{
  "study_id": "NCT00567190",
  "study_title": "Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer (CLEOPATRA)",
  "table_name": "Figure 2B. Subgroup Analysis of Overall Survival",
  "table_title": "Subgroup Analysis of Overall Survival",
  "description": "Subgroup analysis based on baseline patient characteristics. The table presents hazard ratios and 95% confidence intervals for overall survival, comparing the Pertuzumab group to the Control group. The number of patients listed for each subgroup represents the total from both treatment arms combined.",
  "footnotes": [
    "P Value for Interaction is provided for each subgroup category."
  ],
  "groups": [
    {
      "name": "Pertuzumab",
      "n": 402,
      "type": "Pertuzumab + Trastuzumab + Docetaxel"
    },
    {
      "name": "Control",
      "n": 406,
      "type": "Placebo + Trastuzumab + Docetaxel"
    }
  ],
  "characteristics": [
    {
      "original_label": "All patients",
      "standardized_name": "All Participants",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "other",
          "raw_string": "not applicable"
        },
        {
          "group_name": "Control",
          "data_type": "other",
          "raw_string": "not applicable"
        }
      ],
      "comparison_statistics": {
        "statistic_type": "Hazard Ratio",
        "statistic_value": 0.67,
        "p_value": 0.001,
        "notes": "Number of Patients = 808",
        "raw_string": "0.67 (0.55-0.82)"
      }
    },
    {
      "original_label": "Previous adjuvant or neoadjuvant treatment",
      "standardized_name": "Prior Adjuvant or Neoadjuvant Therapy",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Control",
          "data_type": "header",
          "raw_string": ""
        }
      ],
      "comparison_statistics": {
        "statistic_type": "P Value for Interaction",
        "statistic_value": 0.63,
        "p_value": 0.63,
        "raw_string": "0.63"
      }
    },
    {
      "original_label": "No",
      "standardized_name": "No",
      "category": "Prior Adjuvant or Neoadjuvant Therapy",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Previous adjuvant or neoadjuvant treatment",
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "other",
          "raw_string": "not applicable"
        },
        {
          "group_name": "Control",
          "data_type": "other",
          "raw_string": "not applicable"
        }
      ],
      "comparison_statistics": {
        "statistic_type": "Hazard Ratio",
        "statistic_value": 0.64,
        "p_value": 0.63,
        "notes": "Number of Patients = 432",
        "raw_string": "0.64 (0.48-0.85)"
      }
    },
    {
      "original_label": "Yes",
      "standardized_name": "Yes",
      "category": "Prior Adjuvant or Neoadjuvant Therapy",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Previous adjuvant or neoadjuvant treatment",
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "other",
          "raw_string": "not applicable"
        },
        {
          "group_name": "Control",
          "data_type": "other",
          "raw_string": "not applicable"
        }
      ],
      "comparison_statistics": {
        "statistic_type": "Hazard Ratio",
        "statistic_value": 0.7,
        "p_value": 0.63,
        "notes": "Number of Patients = 376",
        "raw_string": "0.70 (0.53-0.93)"
      }
    },
    {
      "original_label": "Region",
      "standardized_name": "Geographic Region",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Control",
          "data_type": "header",
          "raw_string": ""
        }
      ],
      "comparison_statistics": {
        "statistic_type": "P Value for Interaction",
        "statistic_value": 0.36,
        "p_value": 0.36,
        "raw_string": "0.36"
      }
    },
    {
      "original_label": "Europe",
      "standardized_name": "Europe",
      "category": "Geographic Region",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Region",
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "other",
          "raw_string": "not applicable"
        },
        {
          "group_name": "Control",
          "data_type": "other",
          "raw_string": "not applicable"
        }
      ],
      "comparison_statistics": {
        "statistic_type": "Hazard Ratio",
        "statistic_value": 0.65,
        "p_value": 0.36,
        "notes": "Number of Patients = 306",
        "raw_string": "0.65 (0.47-0.91)"
      }
    },
    {
      "original_label": "North America",
      "standardized_name": "North America",
      "category": "Geographic Region",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Region",
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "other",
          "raw_string": "not applicable"
        },
        {
          "group_name": "Control",
          "data_type": "other",
          "raw_string": "not applicable"
        }
      ],
      "comparison_statistics": {
        "statistic_type": "Hazard Ratio",
        "statistic_value": 0.63,
        "p_value": 0.36,
        "notes": "Number of Patients = 135",
        "raw_string": "0.63 (0.37-1.07)"
      }
    },
    {
      "original_label": "South America",
      "standardized_name": "South America",
      "category": "Geographic Region",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Region",
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "other",
          "raw_string": "not applicable"
        },
        {
          "group_name": "Control",
          "data_type": "other",
          "raw_string": "not applicable"
        }
      ],
      "comparison_statistics": {
        "statistic_type": "Hazard Ratio",
        "statistic_value": 0.5,
        "p_value": 0.36,
        "notes": "Number of Patients = 114",
        "raw_string": "0.50 (0.30-0.85)"
      }
    },
    {
      "original_label": "Asia",
      "standardized_name": "Asia",
      "category": "Geographic Region",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Region",
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "other",
          "raw_string": "not applicable"
        },
        {
          "group_name": "Control",
          "data_type": "other",
          "raw_string": "not applicable"
        }
      ],
      "comparison_statistics": {
        "statistic_type": "Hazard Ratio",
        "statistic_value": 0.82,
        "p_value": 0.36,
        "notes": "Number of Patients = 253",
        "raw_string": "0.82 (0.57-1.16)"
      }
    },
    {
      "original_label": "Age",
      "standardized_name": "Age",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Control",
          "data_type": "header",
          "raw_string": ""
        }
      ],
      "comparison_statistics": {
        "statistic_type": "P Value for Interaction",
        "statistic_value": 0.27,
        "p_value": 0.27,
        "raw_string": "0.27"
      }
    },
    {
      "original_label": "<65 yr",
      "standardized_name": "<65 years",
      "unit": "years",
      "category": "Age",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age",
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "other",
          "raw_string": "not applicable"
        },
        {
          "group_name": "Control",
          "data_type": "other",
          "raw_string": "not applicable"
        }
      ],
      "comparison_statistics": {
        "statistic_type": "Hazard Ratio",
        "statistic_value": 0.7,
        "p_value": 0.27,
        "notes": "Number of Patients = 681",
        "raw_string": "0.70 (0.56-0.87)"
      }
    },
    {
      "original_label": "≥65 yr",
      "standardized_name": "≥65 years",
      "unit": "years",
      "category": "Age",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age",
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "other",
          "raw_string": "not applicable"
        },
        {
          "group_name": "Control",
          "data_type": "other",
          "raw_string": "not applicable"
        }
      ],
      "comparison_statistics": {
        "statistic_type": "Hazard Ratio",
        "statistic_value": 0.53,
        "p_value": 0.27,
        "notes": "Number of Patients = 127",
        "raw_string": "0.53 (0.31-0.90)"
      }
    },
    {
      "original_label": "Race or ethnic group",
      "standardized_name": "Race or Ethnicity",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Control",
          "data_type": "header",
          "raw_string": ""
        }
      ],
      "comparison_statistics": {
        "statistic_type": "P Value for Interaction",
        "statistic_value": 0.4,
        "p_value": 0.4,
        "raw_string": "0.40"
      }
    },
    {
      "original_label": "White",
      "standardized_name": "White",
      "category": "Race or Ethnicity",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race or ethnic group",
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "other",
          "raw_string": "not applicable"
        },
        {
          "group_name": "Control",
          "data_type": "other",
          "raw_string": "not applicable"
        }
      ],
      "comparison_statistics": {
        "statistic_type": "Hazard Ratio",
        "statistic_value": 0.63,
        "p_value": 0.4,
        "notes": "Number of Patients = 480",
        "raw_string": "0.63 (0.49-0.82)"
      }
    },
    {
      "original_label": "Black",
      "standardized_name": "Black",
      "category": "Race or Ethnicity",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race or ethnic group",
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "other",
          "raw_string": "not applicable"
        },
        {
          "group_name": "Control",
          "data_type": "other",
          "raw_string": "not applicable"
        }
      ],
      "comparison_statistics": {
        "statistic_type": "Hazard Ratio",
        "statistic_value": 0.41,
        "p_value": 0.4,
        "notes": "Number of Patients = 30",
        "raw_string": "0.41 (0.11-1.45)"
      }
    },
    {
      "original_label": "Asian",
      "standardized_name": "Asian",
      "category": "Race or Ethnicity",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race or ethnic group",
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "other",
          "raw_string": "not applicable"
        },
        {
          "group_name": "Control",
          "data_type": "other",
          "raw_string": "not applicable"
        }
      ],
      "comparison_statistics": {
        "statistic_type": "Hazard Ratio",
        "statistic_value": 0.82,
        "p_value": 0.4,
        "notes": "Number of Patients = 261",
        "raw_string": "0.82 (0.58-1.17)"
      }
    },
    {
      "original_label": "Other",
      "standardized_name": "Other",
      "category": "Race or Ethnicity",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race or ethnic group",
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "other",
          "raw_string": "not applicable"
        },
        {
          "group_name": "Control",
          "data_type": "other",
          "raw_string": "not applicable"
        }
      ],
      "comparison_statistics": {
        "statistic_type": "Hazard Ratio",
        "statistic_value": 0.37,
        "p_value": 0.4,
        "notes": "Number of Patients = 37",
        "raw_string": "0.37 (0.13-1.06)"
      }
    },
    {
      "original_label": "Disease type",
      "standardized_name": "Disease Type",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Control",
          "data_type": "header",
          "raw_string": ""
        }
      ],
      "comparison_statistics": {
        "statistic_type": "P Value for Interaction",
        "statistic_value": 0.03,
        "p_value": 0.03,
        "raw_string": "0.03"
      }
    },
    {
      "original_label": "Visceral",
      "standardized_name": "Visceral",
      "category": "Disease Type",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease type",
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "other",
          "raw_string": "not applicable"
        },
        {
          "group_name": "Control",
          "data_type": "other",
          "raw_string": "not applicable"
        }
      ],
      "comparison_statistics": {
        "statistic_type": "Hazard Ratio",
        "statistic_value": 0.59,
        "p_value": 0.03,
        "notes": "Number of Patients = 630",
        "raw_string": "0.59 (0.48-0.74)"
      }
    },
    {
      "original_label": "Nonvisceral",
      "standardized_name": "Nonvisceral",
      "category": "Disease Type",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease type",
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "other",
          "raw_string": "not applicable"
        },
        {
          "group_name": "Control",
          "data_type": "other",
          "raw_string": "not applicable"
        }
      ],
      "comparison_statistics": {
        "statistic_type": "Hazard Ratio",
        "statistic_value": 1.11,
        "p_value": 0.03,
        "notes": "Number of Patients = 178",
        "raw_string": "1.11 (0.66-1.85)"
      }
    },
    {
      "original_label": "ER or PgR status",
      "standardized_name": "ER or PgR Status",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Control",
          "data_type": "header",
          "raw_string": ""
        }
      ],
      "comparison_statistics": {
        "statistic_type": "P Value for Interaction",
        "statistic_value": 0.47,
        "p_value": 0.47,
        "raw_string": "0.47"
      }
    },
    {
      "original_label": "Positive",
      "standardized_name": "Positive",
      "category": "ER or PgR Status",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ER or PgR status",
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "other",
          "raw_string": "not applicable"
        },
        {
          "group_name": "Control",
          "data_type": "other",
          "raw_string": "not applicable"
        }
      ],
      "comparison_statistics": {
        "statistic_type": "Hazard Ratio",
        "statistic_value": 0.71,
        "p_value": 0.47,
        "notes": "Number of Patients = 388",
        "raw_string": "0.71 (0.53-0.96)"
      }
    },
    {
      "original_label": "Negative",
      "standardized_name": "Negative",
      "category": "ER or PgR Status",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ER or PgR status",
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "other",
          "raw_string": "not applicable"
        },
        {
          "group_name": "Control",
          "data_type": "other",
          "raw_string": "not applicable"
        }
      ],
      "comparison_statistics": {
        "statistic_type": "Hazard Ratio",
        "statistic_value": 0.61,
        "p_value": 0.47,
        "notes": "Number of Patients = 408",
        "raw_string": "0.61 (0.47-0.81)"
      }
    },
    {
      "original_label": "HER2 status",
      "standardized_name": "HER2 Status",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Control",
          "data_type": "header",
          "raw_string": ""
        }
      ],
      "comparison_statistics": {
        "statistic_type": "P Value for Interaction",
        "statistic_value": 0.52,
        "p_value": 0.52,
        "raw_string": "0.52"
      }
    },
    {
      "original_label": "IHC 3+",
      "standardized_name": "IHC 3+",
      "category": "HER2 Status",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "HER2 status",
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "other",
          "raw_string": "not applicable"
        },
        {
          "group_name": "Control",
          "data_type": "other",
          "raw_string": "not applicable"
        }
      ],
      "comparison_statistics": {
        "statistic_type": "Hazard Ratio",
        "statistic_value": 0.66,
        "p_value": 0.52,
        "notes": "Number of Patients = 721",
        "raw_string": "0.66 (0.53-0.81)"
      }
    },
    {
      "original_label": "FISH-positive",
      "standardized_name": "FISH-positive",
      "category": "HER2 Status",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "HER2 status",
      "group_data": [
        {
          "group_name": "Pertuzumab",
          "data_type": "other",
          "raw_string": "not applicable"
        },
        {
          "group_name": "Control",
          "data_type": "other",
          "raw_string": "not applicable"
        }
      ],
      "comparison_statistics": {
        "statistic_type": "Hazard Ratio",
        "statistic_value": 0.69,
        "p_value": 0.14,
        "notes": "Number of Patients = 767",
        "raw_string": "0.69 (0.56-0.85)"
      }
    }
  ]
}